Improvement of the study, analysis, and reporting of adverse events associated with antiretroviral therapy

Lancet

Volumn 360, Issue 9326, 2002, Pages 81-85

  Carr, Andrew ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

BONE DISEASE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FATIGUE; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIPODYSTROPHY; NAUSEA; PANCREATITIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT;

EID: 0037031068     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)09341-8     Document Type: Note

References (22)

1. Adverse effects of antiretroviral therapy
2. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study
3. Impact of adherence and highly active aniretroviral therapy on survival in HIV-infected patients
4. The dynamic of adherence to highly active antiretroviral therapy: Results from the French national APROCO cohort
5. Completeness of safety reporting in randomised trials
6. Quality of life assessment comes of age in the era of highly active antiretroviral therapy
7. Low body weight and type of protease inhibitor predict discontinuation and treatment-limiting adverse drug reactions among HIV-infected patients starting a protease inhibitor regimen: Consistent results from a randomized trial and an observational cohort
8. Predictors of protease inhibitor-associated adverse events
9. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy
10. The revised CONSORT statement for reporting randomised trials: Explanation and elaboration
11. Uniform requirements for manuscripts submitted to biomedical journals